Kamu erişimi zorunlu olan makaleler - Mark R BarakatDaha fazla bilgi edinin
Bir yerde sunuluyor: 7
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two …
CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ...
The Lancet 399 (10326), 741-755, 2022
Zorunlu olanlar: US National Institutes of Health, Juvenile Diabetes Research Foundation
Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map
AM Khanani, MA Zarbin, MR Barakat, TA Albini, PK Kaiser, B Guruprasad, ...
JAMA ophthalmology 140 (1), 20-28, 2022
Zorunlu olanlar: US National Institutes of Health
Frequency of urgent or emergent vitreoretinal surgical procedures in the United States during the COVID-19 pandemic
MP Breazzano, AA Nair, JF Arevalo, MR Barakat, AM Berrocal, JS Chang, ...
JAMA ophthalmology 139 (4), 456-463, 2021
Zorunlu olanlar: US National Institutes of Health
Optical coherence tomography anatomic and temporal biomarkers in uveitic macular edema
TA Ciulla, B Kapik, MR Barakat, RN Khurana, QD Nguyen, DS Grewal, ...
American journal of ophthalmology 237, 310-324, 2022
Zorunlu olanlar: US National Institutes of Health
Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion …
AA Aref, IU Scott, PC VanVeldhuisen, J King, MS Ip, BA Blodi, NL Oden, ...
JAMA ophthalmology 139 (12), 1285-1291, 2021
Zorunlu olanlar: US National Institutes of Health
Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With …
IU Scott, NL Oden, PC VanVeldhuisen, MS Ip, BA Blodi, GA Williams, ...
JAMA ophthalmology 140 (5), 458-464, 2022
Zorunlu olanlar: US National Institutes of Health
Cost-utility comparison of bevacizumab and aflibercept in the treatment of central or hemiretinal vein occlusion in the SCORE2 trial
SM Kymes, NL Oden, PC VanVeldhuisen, IU Scott, MS Ip, BA Blodi, ...
JAMA ophthalmology 141 (6), 554-561, 2023
Zorunlu olanlar: US National Institutes of Health
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir